NCT03000075View on ClinicalTrials.gov

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

December 2, 2016

Primary Completion Date

September 21, 2017

Study Completion Date

June 20, 2018

Conditions

Psoriasis

Interventions

DRUG

risankizumab

Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

DRUG

placebo for risankizumab

Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

Sponsors

Lead Sponsor

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY